Bua M - Search Results

1

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, Clark RE, Apperley JF, Milojkovic D, Bua M, Pavlu J, Paliompeis C, Reid A, Rezvani K, Goldman JM, Foroni L. Marin D, et al. Among authors: bua m. J Clin Oncol. 2012 Jan 20;30(3):232-8. doi: 10.1200/JCO.2011.38.6565. Epub 2011 Nov 7. J Clin Oncol. 2012. PMID: 22067393 Free PMC article.

2

Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia.

Wadhwa J, Szydlo RM, Apperley JF, Chase A, Bua M, Marin D, Olavarria E, Kanfer E, Goldman JM. Wadhwa J, et al. Among authors: bua m. Blood. 2002 Apr 1;99(7):2304-9. doi: 10.1182/blood.v99.7.2304. Blood. 2002. PMID: 11895760 Free article.

3

The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations.

Marin D, Marktel S, Bua M, Armstrong L, Goldman JM, Apperley JF, Olavarria E. Marin D, et al. Among authors: bua m. Haematologica. 2002 Sep;87(9):979-88. Haematologica. 2002. PMID: 12217811 Review.

4

Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate.

Marin D, Marktel S, Foot N, Bua M, Goldman JM, Apperley JF. Marin D, et al. Among authors: bua m. Haematologica. 2003 Feb;88(2):227-9. Haematologica. 2003. PMID: 12604417 No abstract available.

5

Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.

Marktel S, Marin D, Foot N, Szydlo R, Bua M, Karadimitris A, De Melo VA, Kotzampaltiris P, Dazzi F, Rahemtulla A, Olavarria E, Apperley JF, Goldman JM. Marktel S, et al. Among authors: bua m. Haematologica. 2003 Mar;88(3):260-7. Haematologica. 2003. PMID: 12651263 Clinical Trial.

6

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa.

Marin D, Marktel S, Bua M, Szydlo RM, Franceschino A, Nathan I, Foot N, Crawley C, Na Nakorn T, Olavarria E, Lennard A, Neylon A, O'Brien SG, Goldman JM, Apperley JF. Marin D, et al. Among authors: bua m. Leukemia. 2003 Aug;17(8):1448-53. doi: 10.1038/sj.leu.2402996. Leukemia. 2003. PMID: 12886230

7

Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa.

Marin D, Marktel S, Szydlo R, Klein JP, Bua M, Foot N, Olavarria E, Shepherd P, Kanfer E, Goldman JM, Apperley JF. Marin D, et al. Among authors: bua m. Lancet. 2003 Aug 23;362(9384):617-9. doi: 10.1016/S0140-6736(03)14182-7. Lancet. 2003. PMID: 12944062 Clinical Trial.

8

Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse.

Marin D, Kaeda J, Szydlo R, Saunders S, Fleming A, Howard J, Andreasson C, Bua M, Olavarria E, Rahemtulla A, Dazzi F, Kanfer E, Goldman JM, Apperley JF. Marin D, et al. Among authors: bua m. Leukemia. 2005 Apr;19(4):507-12. doi: 10.1038/sj.leu.2403664. Leukemia. 2005. PMID: 15703781

9

Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.

Marin D, Kaeda JS, Andreasson C, Saunders SM, Bua M, Olavarria E, Goldman JM, Apperley JF. Marin D, et al. Among authors: bua m. Cancer. 2005 May 1;103(9):1850-5. doi: 10.1002/cncr.20975. Cancer. 2005. PMID: 15786422 Free article. Clinical Trial.

10

Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy.

Simula MP, Marktel S, Fozza C, Kaeda J, Szydlo RM, Nadal E, Bua M, Rahemtulla A, Kanfer E, Marin D, Olavarria E, Goldman JM, Apperley JF, Dazzi F. Simula MP, et al. Among authors: bua m. Leukemia. 2007 May;21(5):943-8. doi: 10.1038/sj.leu.2404641. Epub 2007 Mar 15. Leukemia. 2007. PMID: 17361226

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Search Page

Filters